Clinical Trial Update: Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the combination of MGCD0103 and docetaxel in advanced cancers has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gastric Cancer
• Lung Cancer
• Non-small Cell Lung Cancer
• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• MGCD0103 (mocetinostat)

Snippet

Sponsor: Mirati Therapeutics Inc. | Conditions: Breast Cancer, Lung Cancer | Phase 1 | Status: TERMINATED